Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NEW YORK, Jan. 04, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company focused on proprietary transdermal delivery today announced that its Adult...
-
DEA Registration granted: expands capability to develop controlled substances via transdermal patches NEW YORK, Oct. 18, 2018 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the...
-
NEW YORK, July 30, 2018 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotech company focused on transforming chemotherapy induced nausea and vomiting (CINV) outcomes...
-
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotech company focused on transforming chemotherapy induced nausea and vomiting (CINV) outcomes...
-
NEW YORK, March 06, 2018 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare”) today announced it will be leveraging novel transdermal patch technology for the treatment of chemotherapy-induced...